Posted: March 13th, 2023
Update on the implementation of the SPC manufacturing waiver into Norwegian law, by Guro Nybø, Nora Bratheim, Lars Erik Steinkjer and Gunnar Meyer, Wikborg Rein Since 2 July 2022, the SPC manufacturing waiver, adopted by the European Parliament in 2019 through Regulation 2019/933, has been available for pharmaceutical manufacturers within the EU. The waiver enables […]
READ MOREPosted: November 7th, 2022
Implementation of the SPC manufacturing waiver into Norwegian law, by Guro Nybø, Nora Bratheim, Lars Erik Steinkjer and Gunnar Meyer, Wikborg Rein The SPC manufacturing waiver was adopted by the European Parliament in 2019 through Regulation 2019/933 amending Regulation (EC) no 469/2009 concerning the supplementary protection certificate for medicinal products (the SPC Regulation). The waiver […]
READ MOREPosted: January 19th, 2021
Introduction The recent decision “Truvada” of the Federal German Supreme Court, dated 22 September 2020 (docket no. X ZR 172/18) is a landmark decision in the field of supplementary protection certificates („SPCs“). According to the decision, the legitimate legal interest (“Rechtsschutzbedürfnis”) for filing a nullity action after the expiry of the term of an SPC […]
READ MOREPosted: October 15th, 2020
Novartis v. Mylan (deferasirox) District Court of The Hague (PI judge Brinkman), 29 September 2020, KG ZA 20-605 Facts The patentee Novartis AG (“Novartis”) is the proprietor of EP 0 914 118 (“EP 118”). EP 118 covers deferasirox, an oral iron chelator that is sold by Novartis under the trademark Exjade. EP 118 is granted […]
READ MOREPosted: October 2nd, 2020
Lacosamide / Commercial Court no. 5 of Barcelona, 14 April 2020, Docket No. 672/2017 / Invalidity action (public availability of a prior art document) & action for threat of patent infringement On 8 September 2017 the plaintiff, LABORATORIOS NORMON, S.A. (hereinafter, “NORMON”) filed an invalidity action against the companies RESEARCH CORPORATION TECHNOLOGIES INC., UCB BIOPHARMA […]
READ MOREPosted: July 10th, 2020
Santen SAS v. Directeur Général de l’Institut national de la propriété industrielle, Court of Justice of the EU, 9 July 2020, Case C‑673/18 “Article 3(d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning […]
READ MOREPosted: May 15th, 2020
Genentech Inc v The Comptroller General of Patents and Master Data Center Inc v Comptroller General of Patents [2020] EWCA Civ 475, 31 March 2020 The Court of Appeal, with Floyd LJ giving the lead judgment, dismissed Master Data Center Inc (“Master Data”) and Genentech Inc’s (“Genentech”) appeals of the High Court decision of Douglas […]
READ MOREPosted: May 15th, 2020
Master Data Center, Inc v The Comptroller General Of Patents [2020] EWHC 572 (Pat), 11 March 2020 In this judgment Douglas Campbell QC dismissed both appeals from Master Data Center Inc (“Master Data”) and Genentech Inc (“Genentech”). The parties were appealing the decision of the Hearing Officer, who held that when a supplementary protection certificate […]
READ MOREPosted: January 13th, 2020
Teva UK Limited and others v Gilead Sciences, Inc. [2019] EWCA Civ 2272 The Court of Appeal has dismissed Gilead Sciences, Inc.’s appeal against a decision by Arnold J (as he then was) that its supplementary protection certificate for a product used in the treatment of HIV was invalid. Background The appellant, Gilead Sciences, Inc. […]
READ MORE